PI, ANNA BAGNATO

Head of Preclinical Models and New Therapeutic Agents Unit

Born in Reggio Calabria, Italy on May 16,1960; Biological Sciences degree at the University Sapienza of Rome in July 1984; Residency in General Pathology at the University Sapienza of Rome in July 1989;1984-1989 Research fellow at the Regina Elena National Cancer Institute (IRE), Rome;1989- 1991: Visiting scientist at the ERRB, NICH, NIH, Bethesda, MD, USA, (K. J. Catt Lab); 1991-Dec.2008: Group Leader at the Molecular Pathology Lab. at IRE.Jan. 2009- Feb.2016:Responsible Lab. "A" Development Therapeutic Programme Department (IRE) Feb.2016-pres:Head of Preclinical Models and New Therapeutic Agents Unit at IRE

PROFESSIONAL ACTIVITIES

- Member of AIRC Technical Scientific Committee(2015-pres)
- Principal Investigator of different grants by public and private agencies and by the industry (1992-pres)
- Reviewing in indexed International journals and in Grant cancer research agencies (2000-pres)
- Member Editorial Board J. Exp. Clin. Cancer Res.(2016- pres)
- Organizing Committee 10-15IntConfEndothelin(2007-2017)
- Organizing Committee 52 Annual Meeting of the Italian Cancer Society (SIC), Rome, Italy 2010
- Member of SIC Director Board (2010-2013)
- Member of different prestigious national and international Award Selection Committee (2011-pres)
- Mentor for undergraduated and PhD students of Universities of Rome, and for fellows granted by public and private agency (2001-pres)
- Lecturer, Chairman or Invited Speaker at numerous international and national meetings (2001-pres)
- Media interviews/Articles (2003-pres)

PROFESSIONAL SOCIETIES

Member Italian Society of Cancerology
Member European Association for Cancer Research
Member American Association Cancer Research
Member Tumor Microenvironment Society

AWARDS

Nature Review Cancer Prize CNIO "Cadherins, Catenins and Cancer", Madrid, November 19-December 1, 2004.
National Award "Virginia Centurione Bracelli", April, 15, 2012

Dr. Bagnato has a long-standing interest in the identification of new targets/signaling pathways associated to early relapse/chemoresistance, in particular in ovarian and colon carcinoma and cutaneous melanoma model, focusing on the GPCR-mediated mechanisms. Concurrently, she lead an international research programme, based on preclinical observations by using endothelin-1 (ET-1) therapeutics that will be trialled clinically, leading to the introduction of novel targeted therapies in ovarian cancer management. Her research has identified the key role of the axis in the development and the progression of cancer and in the acquisition of chemoresistance. The participation to an international network produced important preclinical contributions defining the role of ET-1 axis in human tumors which represent the translational basis that will lead to the introduction of novel targeted therapies in the ovarian cancer management. She is author of 103 scientific publications on peer reviewed journals with a H-index of 39 (Scopus) and a total of 4899 citations. Her work and approach are multidisciplinary; a key skill in translational cancer studies, and her publications have attracted industrial partners (Abbott, AstraZeneca, Actelion, Roche) at different key stages of her work.